Myeloid growth factors clinical practice guidelines in oncology

Jeffrey Crawford; Betsy Althaus; James Armitage; Douglas W. Blayney; Spero Cataland; David C. Dale; George D. Demetri; James Foran; Mark L. Heaney; Sally Htoy; Dwight D. Kloth; Gary H. Lyman; Laura Michaud; Susannah Motl; Saroj Vadhan-Raj; Michael K. Wong

doi:10.6004/jnccn.2005.0030

Myeloid growth factors clinical practice guidelines in oncology

Jeffrey Crawford, Betsy Althaus, James Armitage, Douglas W. Blayney, Spero Cataland, David C. Dale, George D. Demetri, James Foran, Mark L. Heaney, Sally Htoy, Dwight D. Kloth, Gary H. Lyman, Laura Michaud, Susannah Motl, Saroj Vadhan-Raj, Michael K. Wong

Sarcoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

Original language	English (US)
Pages (from-to)	540-555
Number of pages	16
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	3
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2005.0030
State	Published - Jul 2005

Keywords

Chemotherapy
Colony-stimulating factors
Fever
Morbidity
Myeloid growth factors
NCCN Clinical Practice Guidelines
Neutropenia
Toxicity

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2005.0030

Cite this

Crawford, J., Althaus, B., Armitage, J., Blayney, D. W., Cataland, S., Dale, D. C., Demetri, G. D., Foran, J., Heaney, M. L., Htoy, S., Kloth, D. D., Lyman, G. H., Michaud, L., Motl, S., Vadhan-Raj, S., & Wong, M. K. (2005). Myeloid growth factors clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 3(4), 540-555. https://doi.org/10.6004/jnccn.2005.0030

Crawford, J, Althaus, B, Armitage, J, Blayney, DW, Cataland, S, Dale, DC, Demetri, GD, Foran, J, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Michaud, L, Motl, S, Vadhan-Raj, S & Wong, MK 2005, 'Myeloid growth factors clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 4, pp. 540-555. https://doi.org/10.6004/jnccn.2005.0030

@article{1ec40e8a55984948afdc480735420799,

title = "Myeloid growth factors clinical practice guidelines in oncology",

abstract = "Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.",

keywords = "Chemotherapy, Colony-stimulating factors, Fever, Morbidity, Myeloid growth factors, NCCN Clinical Practice Guidelines, Neutropenia, Toxicity",

author = "Jeffrey Crawford and Betsy Althaus and James Armitage and Blayney, {Douglas W.} and Spero Cataland and Dale, {David C.} and Demetri, {George D.} and James Foran and Heaney, {Mark L.} and Sally Htoy and Kloth, {Dwight D.} and Lyman, {Gary H.} and Laura Michaud and Susannah Motl and Saroj Vadhan-Raj and Wong, {Michael K.}",

year = "2005",

month = jul,

doi = "10.6004/jnccn.2005.0030",

language = "English (US)",

volume = "3",

pages = "540--555",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "4",

}

TY - JOUR

T1 - Myeloid growth factors clinical practice guidelines in oncology

AU - Crawford, Jeffrey

AU - Althaus, Betsy

AU - Armitage, James

AU - Blayney, Douglas W.

AU - Cataland, Spero

AU - Dale, David C.

AU - Demetri, George D.

AU - Foran, James

AU - Heaney, Mark L.

AU - Htoy, Sally

AU - Kloth, Dwight D.

AU - Lyman, Gary H.

AU - Michaud, Laura

AU - Motl, Susannah

AU - Vadhan-Raj, Saroj

AU - Wong, Michael K.

PY - 2005/7

Y1 - 2005/7

N2 - Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

AB - Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

KW - Chemotherapy

KW - Colony-stimulating factors

KW - Fever

KW - Morbidity

KW - Myeloid growth factors

KW - NCCN Clinical Practice Guidelines

KW - Neutropenia

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=27744548284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744548284&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2005.0030

DO - 10.6004/jnccn.2005.0030

M3 - Review article

C2 - 16038645

AN - SCOPUS:27744548284

SN - 1540-1405

VL - 3

SP - 540

EP - 555

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Myeloid growth factors clinical practice guidelines in oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this